Letter to the Editor
Automated bedside platelet function assays in patients undergoing percutaneous coronary intervention
First published: 20 December 2001
No abstract is available for this article.
REFERENCES
- 1
Simon DI,
Liu CB,
Ganz P,
Kirshenbaum JM,
Piana RN,
Rogers C,
Selwyn AP,
Popma JJ.
A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
Cathet Cardiovasc Intervent
2001;
52:
425–432.
- 2
Li CKN,
Hoffmann TJ,
Hsieh P-Y,
Malik S,
Watson WC.
The Xylum clot signature analyzer: a dynamic flow system that simulates vascular injury.
Thromb Res
1998;
92:
S67–S77.
- 3
Lages B,
Hoffmann T,
Sun Y,
Li C.
Influence of thrombin and fibrin formation on measurements of hemostasis in native, non-anticoagulated blood using the Xylum clot signature ananlyzer (CSA).
Thromb Haemost
1999(Suppl):
641.
- 4
Arora RR,
Lages B,
Hoffmann T,
Li CKN.
Comparative effects of abciximab and Integrilin on platelets and fibrin formation in native non-anticoagulated blood under flow conditions.
J Am Coll Cardiol
2000;
35:
374A.
